Actively Recruiting
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
Led by University of Arizona · Updated on 2024-10-16
100
Participants Needed
1
Research Sites
570 weeks
Total Duration
On this page
Sponsors
U
University of Arizona
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a stem cell transplant. These donor cells can either be directly infused into the patient or grown in a lab to create more specialized immune cells that target and kill cancer. While this therapy has been helpful for many patients, there is a need to make it more effective for a larger group and reduce side effects like graft-versus-host disease (GvHD), where the donor's immune cells attack the patient's healthy tissue. This Early Phase 1 trial will test whether exercise can help produce better immune cells from donors. The investigators will recruit healthy participants for three study groups: 1. Exercise Group: Participants will complete a 20-minute cycling exercise session. The investigators will collect blood samples before, during, and after exercise to study the number and quality of immune cells. The investigators will also use the collected cells to create immune therapies and test their ability to kill cancer cells in the lab and control cancer growth in mice. 2. Exercise and Beta Blocker Group: In this group, participants will complete up to five cycling sessions, with at least a week between each session. Before each session, participants will take either a placebo or a drug (beta blocker) that blocks stress hormones like adrenaline. The investigators will collect blood samples before and during exercise to see how blocking these hormones changes the effect of exercise on immune cells. 3. Isoproterenol Group: Participants in this group will receive a 20-minute infusion of isoproterenol, a drug that mimics the effects of adrenaline. The investigators will collect blood samples before, during, and after the infusion to see if the drug causes similar immune changes to those caused by exercise. Participants can join one, two, or all three groups. This research will help understand whether exercise can improve immune cell therapies for treating blood cancer and reduce the risk of GvHD, making these treatments safer and more effective.
CONDITIONS
Official Title
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be between 21 and 55 years of age.
- Be classified as 'low-risk' for graded exercise/stress testing according to ACSM-AHA criteria.
- Have no contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast as per FDA guidelines.
You will not qualify if you...
- Currently use tobacco products or have quit within the last 6 months.
- Have a body mass index (BMI) greater than 34 kg/m or waist circumference exceeding 102 cm for men and 88 cm for women.
- Use any medications known to affect the immune system or regularly take ibuprofen/aspirin, antidepressants, or medications that alter blood pressure or cardiovascular function.
- Use of hormone replacement therapy.
- Are pregnant or breastfeeding.
- Have chronic or debilitating arthritis or have been bedridden in the past three months.
- Experienced a common illness (e.g., colds) within the past 6 weeks.
- Have central or peripheral nervous disorders, a history of stroke, or major affective disorder.
- Are infected with HIV or hepatitis or have any autoimmune disease.
- Have known cardiovascular disease or contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast.
- Use any prescription medications or have an allergy to beta-blockers.
- Have a resting heart rate of less than 50 beats per minute.
- Suffer from asthma, emphysema, bronchitis, kidney disease, pheochromocytoma, diabetes, overactive thyroid, or a history of severe anaphylactic reactions.
- Are scheduled for surgery.
- Have more than one cardiovascular disease risk factor unless cleared by a cardiologist, including family history of early heart disease, hypertension, high cholesterol, or pre-diabetes.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Arizona
Tucson, Arizona, United States, 85719
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here